Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 57

Results For "Research"

2113 News Found

Glenmark launches next phase of ‘India First Heart First’ campaign
Healthcare | May 17, 2024

Glenmark launches next phase of ‘India First Heart First’ campaign

35,000 doctors from across India pledged their support for the initiative to raise awareness about cardiovascular diseases


Biocon posts Q4 FY24 PAT at Rs. 135 Cr
News | May 17, 2024

Biocon posts Q4 FY24 PAT at Rs. 135 Cr

EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%


Elinzanetant significantly reduces frequency and severity of hot flashes associated with menopause
Diagnostic Center | May 17, 2024

Elinzanetant significantly reduces frequency and severity of hot flashes associated with menopause

Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms


Cipla invests additional Rs. 26 crore in Achira
News | May 16, 2024

Cipla invests additional Rs. 26 crore in Achira

Achira is engaged in development and commercialization of PoC medical test kits in India


Bayer starts Phase I study with novel targeted radionuclide therapy in advanced metastatic prostate cancer
Diagnostic Center | May 16, 2024

Bayer starts Phase I study with novel targeted radionuclide therapy in advanced metastatic prostate cancer

225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer


AbbVie and Gilgamesh Pharmaceuticals collaborate to develop next-gen therapies for psychiatric disorders
News | May 14, 2024

AbbVie and Gilgamesh Pharmaceuticals collaborate to develop next-gen therapies for psychiatric disorders

Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders


Merck discontinues Phase 3 KeyVibe-010 trial of coformulation of Vibostolimab and Pembrolizumab
Diagnostic Center | May 14, 2024

Merck discontinues Phase 3 KeyVibe-010 trial of coformulation of Vibostolimab and Pembrolizumab

Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria


WACKER expands production capacity for biopharmaceuticals in San Diego
News | May 08, 2024

WACKER expands production capacity for biopharmaceuticals in San Diego

Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA


USFDA accepts Bristol Myers Squibb’s application for subcutaneous nivolumab
Drug Approval | May 08, 2024

USFDA accepts Bristol Myers Squibb’s application for subcutaneous nivolumab

Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor


AstraZeneca completes equity investment agreement with Cellectis
News | May 08, 2024

AstraZeneca completes equity investment agreement with Cellectis

Cellectis is also eligible to receive an investigational new drug (IND) option fee and development